Precision Therapy in Lung Cancer: FAQ on Biomarker Testing and Targeted Therapies

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on biomarker testing and selecting targeted therapy for patients with advanced non-small-cell lung cancer with topics including:

• How to approach discordant results with liquid vs tissue biopsies
• Repeating NGS testing at progression
• Selecting urgent treatment when molecular results are not yet available
• Point mutations in NTRK fusion–positive disease
• Selecting second-line therapy for EGFR-positive disease with high PD-L1 expression after first-line TKI
• Selecting first-line and second-line therapy for ROS1-positive disease
• Standard of care for MET-altered disease
• Selecting second-line therapy for RET fusion–positive disease after first-line TKI

Presenters:

Edward S. Kim, MD, FACP
Chair, Solid Tumor Oncology and Investigational Therapeutics
Donald S. Kim Distinguished Chair for Cancer Research
Levine Cancer Institute
Atrium Health
Charlotte, North Carolina

Leora Horn, MD, MSc, FRCPC
Ingram Associate Professor of Cancer Research
Director, Thoracic Oncology Research Program
Assistant Vice Chairman for Faculty Development
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including associated downloadable slidesets: https://bit.ly/3a3e1Xs

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.